Previous News

2015 

Navitor Pharmaceuticals 

December 18, 2015 - Navitor Pharmaceuticals Announces $33M Series B Financing

View PDF 

 

Proteostasis Therapeutics

December 11, 2015 - Proteostasis Therapeutics Inc. announces management changes to strengthen Research and Development Organization

View PDF 

 

Immune Design

December 7, 2015 - Immune Design Highlights G100 Preclinical Data Demonstrating Direct and Abscopal Tumor Regression, Long-Term Response and Synergy With Checkpoint Blockade

View PDF 

 

Ovid Therapeutics

November 23, 2015 - Ovid Therapeutics Announces Election of Bart Friedman to Its Board of Directors

View PDF 

 

Proteostasis Therapeutics

November 20, 2015 - Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential of a Proprietary Triple Combination Therapy for the Treatment of Cystic Fibrosis that Restores Activity of Mutant F508del CFTR protein to 80% of Normal

View PDF 

 

Immune Design

November 12, 2015 - Immune Design Reports Third Quarter 2015 Financial Results

View PDF 

 

Immune Design

November 11, 2015 - Immune Design Announces Start of Ramdomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma

View PDF 

 

Immune Design

November 3, 2015 - Immune Design Presents Preclinical Data on G100 and ZVex(TM) in Combination With Check Point Inhibitors at the 2015 Society for Immunotherapy of Cancer Annual Meeting
View PDF 

 

Immune Design

October 29, 2015 - MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS(TM) Discovery Platform
View PDF 

 

Unum Therapeutics

October 21, 2015 - Unum Therapeutics Expands Leadership Team by Appointing Dr. Michael J. Vasconcelles as Chief Medical Officer
View PDF 

 

Proteostasis Therapeutics

October 8, 2015 - Proteostasis Therapeutics, Inc. Presents Preclinical Data for Its CFTR Amplifier Program at the 29th Annual North American Cystic Fibrosis Conference
View PDF 

 

Ovid Therapeutics

October 8, 2015 - Ovid Therapeutics Appoints Dr. Jerome B. Zeldis to Its Scientific Advisory Board
View PDF 

 

Unum Therapeutics

September 30, 2015 - Unum Therapeutics selected as a Fierce 15 company
View PDF 

 

Ovid Therapeutics 

September 30, 2015 - Ovid Therapeutics Appoints Dr. Karen Bernstein to its Board of Directors
View PDF 

 

Proteostasis Therapeutics

September 8, 2015 - Proteostasis Therapeutics, Inc. Raises $37 Million in Crossover Financing
View PDF 

 

Selecta Biosciences

September 8, 2015 - Selecta Announces $38 Million Series E Equity Financing 
View PDF 

 

Immune Design

August 12, 2015 - Immune Design Reports Second Quarter 2015 Financial Results 
View PDF 

 

Immune Design

August 12, 2015 - Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 
View PDF 

 

Ovid Therapeutics

August 11, 2015 - Ovid Therapeutics Completes Oversubscribed $75 Million Series B Financing 
View PDF 

 

Immune Design

August 10, 2015 - Immune Design and Merk to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma 
View PDF 

 

Fate Therapeutics

August 5, 2015 - Fate Therapeutics Reports Second Quarter 2015 Financial Results 
View PDF 

 

KaloBios

July 29, 2015 - KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 
View PDF 

 

GlycoMimetics

June 23, 2015 - GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 
View PDF 

 

Unum Therapeutics

June 11, 2015 - Unum Therapeutics Announces $65 Million Series B Financing Round 
View PDF 

 

Unum Therapeutics

June 8, 2015 - Seattle Genetics and Unum Therapeutics Enters Into Strategic Cancer Immunotherapy Collaboration 
View PDF 

 

Fate Therapeutics

June 5, 2015 - Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases
View PDF 

 

Fate Therapeutics

May 20, 2015 - Fate Therapeutics Announces Pricing of Public Offering of Common Stock
View PDF 

 

Fate Therapeutics

May 18, 2015 - Fate Therapeutics Announces Proposed Public Offering of Common Stock
View PDF 

 

Immune Design

May 14, 2015 - Immune Design Reports First Quarter Financial Results
View PDF 

 

Immune Design

May 13, 2015 - Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
View PDF 

 

Fate Therapeutics

May 7, 2015 - Fate Therapeutics Reports First Quarter 2015 Financial Results
View PDF 

 

Fate Therapeutics

May 6, 2015 - Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies
View PDF 

 

Immune Design

April 15, 2015 - Immune Design Prices Public Offering of Common Stock
View PDF 

 

Immune Design

March 31, 2015 - Immune Design Announces Postivie Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents
View PDF 

 

Immune Design

March 31, 2015 - Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
View PDF 

 

Immune Design

March 26, 2015 - Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent
View PDF 

 

Fate Therapeutics

March 12, 2015 - Fate Therapeutics Reports Year-End 2014 Financial Results
View PDF 

 

Fate Therapeutics

March 3, 2015 - Fate Therapeutics Expands and Strengthens Leadership Team
View PDF 

 

Immune Design

February 11, 2015 - Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent
View PDF 

 

Proteostasis Therapeutics

February 4, 2015 - Proteostasis Therapeutics Announces a New Class of Agents for Cystic Fibrosis Called CFTR Amplifiers and Selects PTI130 as a Development Candidate
View PDF 

 

Lysosomal Therapeutics

February 3, 2015 - Lysosomal Therapeutics Inc. Raises $20 Million in Series A Financing
View PDF 

 

Ultragenyx Pharmaceutical

January 12, 2015 - Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
View PDF 

 

Fate Therapeutics

January 12, 2015 - Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
View PDF 

 

Ultragenyx Pharmaceutical

January 7, 2015 - Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
View PDF 

 

2014

Fate Therapeutics

December 18, 2014 - Fate Therapeutics Announces Iterim Data From Ongoing Phase 2 PUMA Study
View PDF 

 

Ultragenyx Pharmaceutical

December 15, 2014 - Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
View PDF 

 

Proteostasis Therapeutics

December 3, 2014 - Proteostasis Therapeutics Announces Appointment of Dr. Po-Shun Lee as Vice President of Clinical Development
View PDF 

 

Immune Design

November 12, 2014 - Immune Design Reports Third Quarter 2014 Financial Results and Provides Corporate Update
View PDF 

 

Fate Therapeutics

November 11, 2014 - Fate Therapeutics Reports Third Quarter 2014 Financial Results
View PDF 

 

Ultragenyx Pharmaceutical

November 10, 2014 - Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
View PDF 

 

Proteostasis Therapeutics

November 6, 2014 - Proteostasis Therapeutics Announces Scientific Publication in Cell Reports
View PDF 

 

Proteostasis Therapeutics

November 4, 2014 - Proteostasis Therapeutics and Astellas Announce Collaboration for Research, Development and Commercialization of Therapies Modulating the Unfolded Protein Response
View PDF 

 

Unum Therapeutics

October 21, 2014 - Fidelity Biosciences and Atlas Venture Lead $12 Million Series A Funding to Launch Unum Therapeutics, a New Cellular Immunotherapy Company
View PDF 

 

Proteostasis Therapeutics

October 20, 2014 - Proteostasis Therapeutics Announces Appointments of Cystic Fibrosis Experts to Inaugural Clinical Advisory Board
View PDF 

 

Immune Design

October 16, 2014 - Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
View PDF 

 

Ultragenyx Pharmaceutical

October 13, 2014 - Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
View PDF 

 

Immune Design

October 2, 2014 - Immune Design Added to Russell 2000(R) Index
View PDF 

 

Ultragenyx Pharmaceutical

September 15, 2014 - Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients with X-Linked Hypophosphatemia
View PDF 

 

Ultragenyx Pharmaceutical

September 3, 2014 - Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucruronidase in Mucopolysaccharidosis 7
View PDF 

 

KaloBios

August 14, 2014 - Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
View PDF 

 

Fate Therapeutics

August 12, 2014 - Fate Therapeutics Reports Second Quarter 2014 Financial Results
View PDF 

 

Ultragenyx Pharmaceutical

August 11, 2014 - Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
View PDF 

 

Immune Design

August 7, 2014 - Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy
View PDF 

 

Ultragenyx Pharmaceutical

August 5, 2014 - Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin
View PDF 

 

Fate Therapeutics

July 31, 2014 - Fate Therapeutics Secures Up to $20 Million in Debt Financing
View PDF 

 

Proteostasis Therapeutics

July 30, 2014 - Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
View PDF 

 

Fate Therapeutics

July 29, 2014 - Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
View PDF 

 

Immune Design

July 24, 2014 - Immune Design Announces Pricing of Initial Public Offering
View PDF 

 

Ultragenyx Pharmaceutical

July 14, 2014 - Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
View PDF 

 

Ultragenyx Pharmaceutical

July 9, 2014 - Ultragenyx Announces Pricing of Public Offering of Common Stock
View PDF 

 

Ultragenyx Pharmaceutical

July 1, 2014 - Ultragenyx Announces Initiation of a Phase 2 Study of KN23 for Pediatric X-Linked Hypophosphatemia in the US and EU
View PDF 

 

Fate Therapeutics

June 30, 2014 - Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders
View PDF 

 

Ultragenyx Pharmaceuticals

June 24, 2014 - Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
View PDF 

 

Fate Therapeutics

June 5, 2014 - Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo
View PDF 

 

Immune Design

June 5, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent
View PDF 

 

Edimer Pharmaceuticals

May 28, 2014 - Edimer Pharmaceuticals' EDI200 Expands to Higher Dose Cohort in Phase 2 Trial Following Positive Review of Safety Data
View PDF 

 

Immune Design

May 27, 2014 - Immune Design's GLAAS Discovery Platform Used in MEDI7510 Phase 1 Trial for Respiratory Syncytial Virus
View PDF 

 

Fate Therapeutics

May 13, 2014 - Fate Therapeutics Reports First Quarter 2014 Financial Results
View PDF 

 

Lysosomal Therapeutics

May 12, 2014 - Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
View PDF 

 

Ultragenyx Pharmaceutical

May 12, 2014 - Ultragenyx Reports First Quarter 2014 Financial Results and Corporate Update
View PDF 

 

KaloBios

May 8, 2014 - KaloBios Provides First Quarter 2014 Financial Results
View PDF 

 

Ultragenyx Pharmaceutical

April 30, 2014 - Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
View PDF 

 

Fate Therapeutics

April 23, 2014 - Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
View PDF 

 

Fate Therapeutics

April 10, 2014 - Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
View PDF 

 

MacroGenics

April 6, 2014 - MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity with Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
View PDF 

 

Edimer Pharmaceuticals

April 1, 2014 - Edimer Pharmaceuticals Presents Update on Phase 2 Clinical Trial of ED1200 at International Gathering of Ectodermal Dysplasia Patient Foundations
View PDF 

 

Ultragenyx Pharmaceutical

March 27, 2014 - Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
View PDF 

 

Ultragenyx Pharmaceutical

March 24, 2014 - Ultragenyx Reports Fourth Quarter and Full Year 2013 Financial Results
View PDF 

 

MacroGenics

March 20, 2014 - MacroGenics Provides Update on Corporate Progress and 2013 Financial Results
View PDF 

 

Immune Design

March 18, 2014 - Immune Design Appoints Franklin M. Berger to Board of Directors
View PDF 

 

Fate Therapeutics

March 17, 2014 - Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
View PDF 

 

KaloBios

March 13, 2014 - KaloBios Announces Fiscal Year 2013 Financial Results
View PDF 

 

Fate Therapeutics

March 12, 2014 - Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies Type-1 Deficiency Syndrome
View PDF 

 

Ultragenyx Pharmaceutical

March 11, 2014 - Ultragenyx Announces First Patient Enrolled in Phase 2 Study of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
View PDF 

 

Immune Design

March 6, 2014 - Immune Design Appoints William Ringo to Board of Directors
View PDF 

 

Fate Therapeutics

March 6, 2014 - Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
View PDF 

 

Immune Design

February 27, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G305 Cancer Immunotherapy Agent
View PDF 

 

Fate Therapeutics

February 26, 2014 - Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
View PDF 

 

Ultragenyx Pharmaceutical

February 11, 2014 - Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders
View PDF 

 

KaloBios

February 11, 2014 - KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
View PDF 

 

Ultragenyx Pharmaceutical

February 6, 2014 - Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
View PDF 

 

Ultragenyx Pharmaceutical

January 30, 2014 - Ultragenyx Announces Pricing of Initial Public Offering
View PDF 

 

Immune Design

January 27, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G100, an Investigational Immuno-Oncology Agent
View PDF 

 

GlycoMimetics

January 9, 2014 - GlycoMimetics Announces Pricing of Initial Public Offering
View PDF 

 

2013

Ultragenyx

December 20, 2013 - Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
View PDF 

December 4, 2013 - Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)
View PDF 

 

Ultragenyx

December 20, 2013 - Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
View PDF 

December 4, 2013 - Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)
View PDF 

 

bluebird bio

December 2, 2013 - bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia
View PDF 

 

Immune Design

October 30, 2013 - Immune Design Raises Up to $49 Million Series C Financing
View PDF 

 

KaloBios

October 30, 2013 - U.S. FDA Grants Orphan Drug Designation for KaloBios' KB001 - A in Treatment of Cystic Fibrosis Patients
View PDF 

 

Proteostasis Therapeutics

October 18, 2013 - Proteostasis Therapeutics Presents Promising Preclinical Data at the 27th Annual North American Cystic Fibrosis Conference
View PDF 

 

Edimer

October 8, 2013 - Edimer Initiates Phase 2 Trial of EDI200 in XLHED-Affected Male Newborns
View PDF 

 

Fate Therapeutics

October 4, 2013 - Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
View PDF 

 

KaloBios

September 26, 2013 - KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
View PDF 

 

GlycoMimetics

September 13, 2013 - GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease
View PDF 

 

Edimer

July 30, 2013 - Edimer Secures $18M Series B Financing Led by New Enterprise Associates
View PDF 

 

bluebird bio

June 24, 2013 - bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
View PDF 

 

KaloBios

April 23, 2013 - U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
View PDF 

 

Fate Therapeutics

April 22, 2013 - Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference
View PDF 

 

GlycoMimetics

April 16, 2013 - GlycoMimetics Announces Top Line Results from Phase 2 Trial with GMI-1070 in Sickle Cell Disease
View PDF 

 

Kahr Medical

February 4, 2013 - KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
View PDF 

 

2012

Ultragenyx

December 19, 2012 - Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing
View PDF